AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04597320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.05mg/kg+ Anesthesia inducer was applied to all patients for procedural induction by intravenous injection. According to the MOAA/S score of the patients, midazolam could be added 0.5mg per time at more than 2 minutes until the MOAA/S score reached 3, the maximum infusion dose of midazolam was less than 10mg and less than 0.1mg/kg.
Study NCT04737941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothermal Ablation
Description: Endothermal ablation is performed to suitable insufficient truncal veins (Great-, Anterior Accessory- and/or Small Saphenous Vein)
Study NCT04737941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothermal Ablation
Description: Endothermal ablation is performed to suitable insufficient truncal veins (Great-, Anterior Accessory- and/or Small Saphenous Vein)
Study NCT04737941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foam Sclerotherapy
Description: Foam sclerotherapy is performed to insufficient veins distal to the truncal superficial veins.
Study NCT04737941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foam Sclerotherapy
Description: Foam sclerotherapy is performed to insufficient veins distal to the truncal superficial veins.
Study NCT04557618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation
Description: Transcutaneous auricular vagal nerve stimulation
Study NCT05067972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07260437
Description: B7-H4 x CD3 bi-specific mAb
Study NCT04557618 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular Vagus nerve Stimulation
Description: Transcutaneous auricular vagal nerve ear clip applied without current
Study NCT06132685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06132685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05067972 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: B7-H4 IHC
Description: B7-H4 expression
Study NCT05189288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D418 Tab.
Description: 1T
Study NCT05189288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-388 Tab.
Description: 1T
Study NCT06132685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given dexamethasone or IV
Study NCT06132685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06132685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04633889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: Deferoxamine 30mg/kg (max dose, 6g) intravenous infusion (diluted in 240mL normal saline) administered over 12 hours
Study NCT04633889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (240mL) intravenous infusion over 12 hours
Study NCT04971915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: minimalist footwear
Description: The intervention consists of wearing the minimalist footwear in recommended progression during the interventional period (6months). The intial load starts at 2,500 steps a day and will be gradually increased up according to the participant´s tolerance rate to the footwear wearing to fully use over the final period. Participants are instructed to report all issues and difficulties possibly connected to the intervention. There will be the opportunity to consult any issue connected with footwear or their wearing through the duration of the research.
Study NCT06301633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The specific procedure was as follows: the infant was placed in a semi-recumbent or sitting position with the head fixed. Before each feeding, the infant's oral and nasal secretions were to be cleared. An intermittent oro-esophageal tube was appropriately lubricated with water on the head part. The professional medical staff held the tube and slowly inserted it through one side of the mouth into the upper part of the esophagus. The depth of insertion depended on the patient's age and height. After each feeding, the tube was immediately removed, and the patient was held upright for at least 30 minutes in case of reflux.
Study NCT06301633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study NCT06301633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06301633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06114446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: simulation group
Description: Participants will be educated with simulation manikin for postoperative nursing care of a patient who underwent colorectal surgery
Study NCT06114446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersive virtual reality
Description: Participants will be educated with immersive virtual simulation f for postoperative nursing care of a patient who underwent colorectal surgery
Study NCT06114446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: observation
Description: All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills
Study NCT06114446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observation
Description: All participants who participate in simulation or immersive virtual arms will be observed to assess postoperative nursing care skills
Study NCT05263583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sepantronium Bromide
Description: continuous intravenous infusion
Study NCT05193019 — intervention group
Intervention type: OTHER
Intervention: Parenteral antiplatelet agents
Description: Patients undergoing PCI and receiving parenteral antiplatelet agents, cangrelor or glycoprotein IIb/IIIa inhibitors (GPIs), during the procedure as per clinical practice
Study NCT04894604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance® Solo NPWT System
Description: Application of the Avance® Solo NPWT System on up to 34 study Subjects, in accordance with the IfU for up to 14 days.
Study NCT06094010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered as oral suspension either as 2 milligrams per kilograms (mg/kg) (if weight less than 20 kg), or 40 mg (if weight more than or equal to 20 kg to less than 80 kg) or 80 mg (if weight more than or equal to 80 kg).
Study NCT06188780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urine/blood analysis with IA and LC-GCMS analysis
Description: urine/blood analysis with IA and LC-GCMS analysis
Study NCT06192888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: IV Glofitamab
Study NCT06192888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: IV Obinutuzumab
Study NCT06192888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Lenalidomide
Study NCT06575218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality training
Description: Virtual reality training
Study NCT06575218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise and cognitive exercise
Description: Conventional exercise and cognitive exercise
Study NCT06575218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention
Study NCT04571619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Coping Skills Training (PCST)
Description: The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.
Study NCT04571619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
Study NCT04571619 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be encouraged to switch from their current full agonist opioid medication to the partial opioid agonist, buprenorphine. Participants who switch to Buprenorphine will be provided with individualized buprenorphine treatment recommendations. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants who do not meet the Phase 2 eligibility criteria will not be offered buprenorphine. All participants will continue to be followed from Week 24 until Week 36 for ascertainment of pain, opioid use, and other outcomes to address durability of the effects of PCST, and, for those who switch to buprenorphine, to assess buprenorphine acceptability, tolerability, and efficacy as exploratory outcomes.
Study NCT06547879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension Self Management Program
Description: The HT self-management training program was continued in the form of one session per week, a total of 8 modules, for 8 weeks, with different module content each week. After these eight-week training and awareness sessions were completed, the implementation of the study was terminated (week 8), no additional intervention was given to the intervention group, and the evaluations at the 8th week (end of intervention-T1) and the 12th week (follow-up-T2) were carried out by the researcher during the routine checks of the participants at the outpatient clinic. It was carried out face to face.
Study NCT06546436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CARC-101C
Description: Subjects enrolled in the project will received a one-dose injection of CARC-101C
Study NCT05907200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combination ultrasound therapy and manual therapy
Description: The proposed manual therapy lasted 90 minutes and involved a combination of three different techniques: McMennel manipulation, connective tissue massage and mobilization technique of pumping. Patients in the treatment group also received a treatment with US (I-Tech medical device certified UT2 CE0476) in combination with manual therapy. Dipping technique was applied with a frequency of 1 MHz, intensity of 1W/cm2, duty cycle of 60% and a duration of 15 minutes per session.
Study NCT05907200 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: manual therapy
Description: manual treatment lasting 90 minutes which involved a combination of three different techniques: McMennel manipulation, connective tissue massage and pumping mobilization technique.
Study NCT05105711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QI coaching intervention
Description: The intervention consists of two main components: a webinar communication workshop and use of the Checkup Coach mobile app. The Checkup Coach intervention begins with a brief (\<1 hour), communication training workshop that reviews evidence on HPV vaccination, models guideline-consistent recommendations, trains providers to address parent concerns, and facilitates discussion of shared goals for improving. Next, providers are invited to download and use the Checkup coach mobile app at their discretion for the 12-week study period. Providers complete in-app self-assessments and receive tailored feedback about their HPV vaccine recommendation quality, progress toward improving recommendation practices, a dashboard of aggregate HPV vaccination coverage for patients in their clinic, and tips for addressing parents' concerns about HPV vaccination every time they use the app.
Study NCT06485037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Self-selected 10-hour eating window for 2 months
Study NCT05723627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion.
Study NCT05723627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients in this group receives 0.5mg/kg of propofol to induce sedation prior to endoscope insertion.
Study NCT04978285 — intervention group
Intervention type: OTHER
Intervention: Anemia
Description: Depends on Day 3 Hb result
Study NCT04866485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003 and pembrolizumab
Description: Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
Study NCT04398524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISA101b
Description: ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
Study NCT05289804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NITESGON
Description: NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain.
Study NCT05289804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NITESGON
Description: NITESGON will be delivered by a specially developed, battery-driven, constant current stimulator via a pair of saline-soaked surface sponges on the scalp. One electrode each will be placed over the left and right C2 dermatomes.~NITESGON will first be switched on in a ramp-up fashion over 30 seconds. For active NITESGON, stimulation will occur during the word association task. For sham the current intensity (ramp down) will gradually be reduced (over 5 seconds) as soon as NITESGON reaches a current flow of 1.5 mA. The rationale behind this sham procedure is to mimic the transient skin sensation at the beginning of active NITESGON without producing any conditioning effects on the brain.
Study NCT05289804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine / Prilocaine Topical Cream
Description: A topical skin anesthetic (lidocaine/prilocaine cream) will be used to reduce any potential contribution from transcutaneous stimulation of peripheral nerves. This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin and thereby stabilizes the membrane potential and increases the threshold for firing an action potential.
Study NCT05289804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C5/C6 stimulation
Description: The electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location.
Study NCT05289804 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NITESGON
Description: Sham NITESGON
Study NCT03602898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT03602898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or PO
Study NCT03602898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05887479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Toxin of Clostridium Botulinum
Study NCT05887479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: %0,9 NaCl
Description: %0,9 NaCl
Study NCT04793555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring by unobtrusive sensors
Description: During the study the behavior of daily activities will be monitored by unobstructive sensors. Most of the sensors will be mounted on the wall or on furniture with direct sight to the participant and thus will not have any physical contact, except some wearables during the stay in the apartment and at home (e.g. watch, mobile polysomnography).
Study NCT04719793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-derived Wharton's Jelly
Description: Intraarticular injection
Study NCT05295498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active repetitive transcranial magnetic stimulation
Description: High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
Study NCT05295498 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham stimulation to mimic the high frequency rTMS over the primary motor area.
Study NCT06195553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPPS plus Family Connections
Description: The intervention will be based on cognitive and behavior treatment using STEPPS for the patients and dialectical and behavior treatment using Family Connections for the families. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Main components Family Connections: psychoeducation, skills training and peer support.
Study NCT06195553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STEPPS
Description: The intervention will be based on cognitive and behavior treatment using STEPPS for the patients. Main components STEPPS: psychoeducation, emotional regulation skills and behavioral regulation skills. Waiting list group: Participant's relatives of this group will be able to receive the Family Connections intervention after the research end.